Trial Profile
Interventional, Open-label, Three-group Study to Determine the Pharmacokinetic Properties of Single Oral Dosing of Lu AE58054 in Patients With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Idalopirdine (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 17 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2014 New trial record